To hear about similar clinical trials, please enter your email below
Trial Title:
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
NCT ID:
NCT00180791
Condition:
Medulloblastoma
Brain Tumors
Neuroectodermal Tumors, Primitive
Conditions: Official terms:
Neoplasms
Brain Neoplasms
Medulloblastoma
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Carboplatin
Etoposide
Melphalan
Thiotepa
Conditions: Keywords:
Brain PNET
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Unknown status
Study design:
Allocation:
Non-Randomized
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Etoposide, carboplatin, melphalan, cisplatin, thiotepa
Summary:
The purpose of this study is to evaluate the efficacy of the combination of surgery,
conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem
cell transplantation and reduced dose radiation therapy in high-risk PNET brain tumors.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Medulloblastoma in patients less than 5 years of age
- Brain PNET in patients less than 10 years of age
- Histologically documented diagnosis
- Body weight of > 8 kg
Exclusion Criteria:
- Parents' refusal
Gender:
All
Minimum age:
N/A
Maximum age:
10 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Institut Gustave Roussy
Address:
City:
Villejuif
Zip:
94800
Country:
France
Status:
Recruiting
Contact:
Last name:
Chantal Kalifa, MD
Phone:
33 1 42 11 4166
Email:
kalifa@igr.fr
Start date:
July 2002
Lead sponsor:
Agency:
Gustave Roussy, Cancer Campus, Grand Paris
Agency class:
Other
Source:
Gustave Roussy, Cancer Campus, Grand Paris
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT00180791
